REGENXBIO director awarded RSUs and stock options

REGENXBIO Inc. reported that director Alexandra Glucksmann received new equity awards.

Rhea-AI Filing Summary

REGENXBIO Inc. reported that director Alexandra Glucksmann received new equity awards. She was granted 9,807 shares of Common Stock in the form of a time-based restricted stock unit award, which will vest 100% on May 29, 2027 if she continues service with the company.

She was also granted stock options covering 46,600 shares of Common Stock at an exercise price of $7.01 per share. These options will vest on May 29, 2027 and expire on May 29, 2036. Following the grants, she directly holds 28,861 Common Stock shares and 46,600 options. These are compensation awards rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 56,407 shares

Grant/Award 2 txns

Insider Glucksmann Alexandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	46,600	$0.00	$0.00
Grant/Award	Common Stock	9,807	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 46,600 contracts (Direct); Common Stock — 28,861 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
2. F2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Key Figures

RSU shares granted: 9,807 shares Options granted: 46,600 options Option exercise price: $7.01 per share +4 more

7 metrics

RSU shares granted 9,807 shares Time-based RSU award vesting May 29, 2027

Options granted 46,600 options Stock Options (Right to Buy) granted May 29, 2026

Option exercise price $7.01 per share Conversion/exercise price for 46,600 options

Option vesting date May 29, 2027 Vesting date for stock options and RSU award

Option expiration May 29, 2036 Expiration date for 46,600 stock options

Shares held after grant 28,861 shares Total Common Stock directly held after RSU grant

Options held after grant 46,600 options Total stock options directly held after grant

Key Terms

restricted stock unit award (RSU), Stock Options (Right to Buy), exercise price, vesting, +1 more

5 terms

restricted stock unit award (RSU) financial

"Represents shares of common stock underlying a time-based restricted stock unit award (RSU)."

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.0100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to this RSU will vest on May 29, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-05-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did REGENXBIO (RGNX) report for Alexandra Glucksmann?

REGENXBIO reported that director Alexandra Glucksmann received equity compensation grants, not open-market trades. She was awarded 9,807 RSU shares and stock options on 46,600 shares, all granted on May 29, 2026, subject to future vesting conditions.

How many RSU shares did Alexandra Glucksmann receive at REGENXBIO (RGNX)?

She received a restricted stock unit award covering 9,807 shares of REGENXBIO common stock. All RSU shares are scheduled to vest on May 29, 2027, provided she maintains continuous service with the company through that vesting date.

What are the terms of Alexandra Glucksmann’s stock options at REGENXBIO (RGNX)?

She was granted stock options for 46,600 REGENXBIO common shares at an exercise price of $7.01 per share. These options vest on May 29, 2027 and have an expiration date of May 29, 2036, giving a long exercise window.

Are Alexandra Glucksmann’s REGENXBIO (RGNX) equity awards immediately vested?

No, both awards are subject to future vesting. The 9,807 RSU shares and the 46,600 stock options each vest on May 29, 2027, conditioned on Ms. Glucksmann’s continuous service to REGENXBIO through that date.

How many REGENXBIO (RGNX) shares does Alexandra Glucksmann hold after these grants?

After the reported grants, she directly holds 28,861 shares of REGENXBIO common stock. In addition, she holds stock options covering 46,600 shares, which become exercisable after vesting on May 29, 2027, at an exercise price of $7.01.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 05:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glucksmann Alexandra

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		A		9,807(1)	A	$0.00	28,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$7.01	05/29/2026		A		46,600		05/29/2027(2)	05/29/2036	Common Stock	46,600	$0.00	46,600	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

2. The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)